Enrollment and endpoint platform for retinal gene-therapy trials that finds eligible patients faster and proves functional vision change.

1. Capital is now available for execution infrastructure because retinal optogenetics has attracted a nine-figure Series B rather than a small research round.
2. Gene-agnostic approaches increase the need for phenotype-driven patient finding across broader retinal populations, which makes specialized recruitment software more valuable.
3. Active clinical studies make enrollment throughput and site readiness immediate budget items, not future planning topics.
4. Multiple indications on the same platform create a path for one workflow layer to serve retinitis pigmentosa, Stargardt disease, and geographic atrophy programs.

Catalyst. Ray's $125M financing and active ENVISION plus RTx-021 enrollment mean retinal optogenetics is now capitalized enough that enrollment speed and endpoint quality can determine program value.

The product gives sponsors and retina sites a shared operating layer for recruitment and endpoint collection. Sites can intake referrals, upload prior diagnosis and visual-function records, and receive a structured protocol-fit checklist that reduces manual back-and-forth with sponsors. Patients who appear eligible are then enrolled into a standardized remote assessment flow that tracks low-vision functional tasks between visits and packages the results into sponsor-ready longitudinal reports. Over time, the company builds a retina-specific dataset on referral conversion, screen-failure causes, site performance, and disease-specific functional outcomes that improves study design and site selection for later programs.

What's different. Generic trial-tech vendors handle forms, randomization, or broad ePRO workflows, but they do not own the retinal-disease-specific work of protocol-fit review and functional vision tracking. This company starts where sponsor teams actually lose time: identifying rare low-vision patients, explaining screen failures, and producing usable longitudinal evidence between site visits. Its defensibility comes from a proprietary retina trial graph spanning referral sources, eligibility patterns, site performance, and disease-specific functional outcomes.

Jobs to be done

flowchart LR
  Buyer[Clinical Ops Lead] --> Pain[Slow enrollment and noisy vision endpoints]
  Pain --> Product[Retina trial readiness OS]
  Product --> Outcome[Faster recruitment and stronger longitudinal evidence]

Executive takeaways

• There is a real operational wedge, but the initial beachhead is small; as a standalone retina-trial SaaS business it looks niche unless it expands quickly into adjacent ophthalmology workflows [1][3][4][5][6][7].
• Why now is credible: Ray has $125M in fresh financing and RMAT, while Nanoscope, Beacon, and Ocugen all show active late-stage or pivotal retinal programs [1][2][4][5][6][7][26].
• The strongest non-obvious insight is that mutation-agnostic therapies increase the importance of phenotype-driven triage and functional endpoint capture, not just genotype matching [1][4][6][7][21][22][23].
• Horizontal vendors already occupy adjacent budget lines, but none appears retina-native in public materials; that gives the startup a specialization wedge and a bundling risk at the same time [8][9][10][11][12][13][14].
• Endpoint credibility is the hardest product risk. Recent IRD literature argues standard visual acuity is often insufficient, but alternative measures still need validation and careful regulatory framing [2][22][23][24].
• Buyer power is high because the likely buyers are a small number of sophisticated ocular-gene-therapy sponsors, so proof of ROI must be concrete and fast [1][5][6][8][9][11][12].

Market definition

The market is not retinal therapeutics revenue. It is workflow and evidence software sold to sponsor clinical-operations teams and retina sites running interventional retinal studies, initially for RP and Stargardt programs in the U.S. and later the EU. Excluded: core EDC/CTMS, CRO labor, manufacturing, diagnostics, and drug sales themselves [3][8][12][18][19][20].

Customer and buyer

Primary users are sponsor clinical-ops staff and retina-site coordinators. The economic buyer is most likely the VP Clinical Operations or CMO at an ocular gene-therapy sponsor. Budget likely comes from recruitment, eCOA, or decentralized-trial spend already going to incumbents, not from a brand-new category budget [8][9][10][11][12][13][14].

Buying triggers

• A retinal study opens and qualified patients are scarcer than planned. [3][5][6][7][21][25]
• Investigators and sponsors struggle to collect meaningful functional-vision evidence between visits. [2][22][23]
• A program moves into registrational planning or commercialization prep and operational rigor matters more. [2][5][6][26]

Willingness to pay

Willingness to pay exists when the product can reduce enrollment delay, lower screen failures, or improve endpoint quality. Public vendor claims show sponsors already pay for recruitment, site-collaboration, DCT, and eCOA layers with measurable operational ROI; a retina-specific product must displace spend inside those buckets [8][9][10][11][12][13][14]. [8][9][10][11][12][13][14]

Category dynamics

Growth signal 7.79%-15.07% CAGR

Validation signals

• Ray raised $125M in Series B.
• Ray received RMAT for RTx-015.
• Nanoscope is publicly discussing commercial readiness and BLA preparation.
• Beacon has both enrolling and pivotal XLRP studies.
• Ocugen is running Phase 3 RP and Phase 2/3 Stargardt studies.
• The FFB pipeline shows multiple active retinal therapy programs across modalities.

Regulatory & technical constraints

• Remote functional-vision measures need fit-for-purpose validation before they influence critical trial decisions.
• Rare-disease DHT adoption is rising, but implementation and data-integration burden remain real.
• EU workflows need to fit CTIS and the Clinical Trials Regulation.
• Patient-finding advantage depends on access to specialized registries and referral networks, not just broad consumer marketing.
• Any product touching regulated-trial data must coexist with incumbent eCOA, site, and sponsor systems.

Veeva owns broad sponsor-site workflow, Medable and Science 37 own generalized decentralized operations, Signant owns regulated COA expertise, and Trialbee owns top-of-funnel recruitment. The proposed startup is narrower: retinal protocol-fit review and functional-vision evidence orchestration. That makes the wedge intelligible, but also makes bundling by incumbents the default strategic threat [8][9][10][11][12][13][14].

Why incumbents do not win by default

• Clinical cloud platforms. Veeva wins by breadth, not by retina-specific depth. Its public materials show strong site collaboration and startup workflows, but not phenotype-specific retinal qualification or low-vision evidence logic [12].
• Decentralized trial platforms. Science 37 and Medable can deliver remote operations, yet their positioning is cross-therapeutic and service-heavy. A retina-native layer can be narrower and more opinionated [8][9][11].
• COA specialists. Signant is strong on endpoint implementation and regulatory support, but not visibly on retinal referral workflows or site-readiness orchestration [13][14].
• Recruitment vendors. Trialbee can improve top-of-funnel quality, but it does not appear to own retina-specific eligibility logic or downstream longitudinal endpoint capture [10].
• In-house and CRO workflows. Manual workflows can run one study, but they do not compound learning across rare-disease referrals, exclusion reasons, and site performance [9][21].

Retina Trial Readiness OS is a workflow and evidence layer for retinal gene-therapy sponsors running small, multi-site studies in inherited retinal disease. The initial customer is the VP Clinical Operations or CMO at a U.S.-based retinal therapy company opening or expanding a retinitis pigmentosa trial and struggling to find protocol-fit patients fast enough. The product combines retina-specific referral triage, structured protocol-fit review, and at-home functional vision tracking so sponsors can reduce screen failures and collect denser longitudinal evidence between visits. The market is real but narrow: the researched beachhead supports only a small standalone software business unless the company expands quickly into adjacent ophthalmology workflows such as Stargardt disease, geographic atrophy, and post-treatment monitoring. The best go-to-market motion is founder-led sales into active studies, priced as a study subscription plus per-enrolled-patient workflow fees and attached to existing recruitment, eCOA, or decentralized-trial budgets rather than a new software line item. The core strategic advantage is disease-specific workflow depth and a compounding dataset on referral quality, exclusion reasons, site performance, and functional vision change that horizontal vendors do not appear to own publicly today. The hardest product risk is endpoint credibility, so the first release should position remote assessments as operational and exploratory evidence rather than primary endpoint replacement. Public evidence supports urgency and buyer pain, but exact budget ownership, acceptable remote tasks, and the pace of adjacent-market expansion remain operating assumptions that must be tested early.

Problem

• Rare-retina trials rely on fragmented referral networks, manual chart review, and coordinator spreadsheets, which slows time to first qualified patient and drives avoidable screen failures.
• Functional vision change in low-vision populations is hard to observe between site visits, so efficacy signals are sparse and noisy when sponsors need early operational and program decisions.

Solution

• Sponsor and site teams share a retina-specific intake and protocol-fit workflow that standardizes referral review, documents exclusion reasons, and surfaces likely eligible patients faster.
• Patients who pass triage enter a structured remote assessment flow that captures repeatable functional vision tasks between visits and packages longitudinal outputs into sponsor-ready reports.

Why we win

• The wedge starts at a high-cost bottleneck that generic CTMS, eCOA, recruitment, and CRO workflows do not address with retinal phenotype and low-vision specificity.
• Each deployment creates proprietary data on referral conversion, site performance, and functional outcome patterns that can improve later protocol design, site selection, and expansion into adjacent ophthalmology studies.

Milestones

flowchart LR
  Wedge[RP sponsor enrollment wedge] --> MVP[Referral triage plus protocol-fit MVP]
  MVP --> Proof[Faster qualification and denser longitudinal evidence]
  Proof --> Expansion[Stargardt and GA study expansion]
  Expansion --> Moat[Retina workflow data and benchmark moat]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 3 of the first 10 sponsor buyers confirm they can reallocate existing recruitment, eCOA, or DCT budget to a retina-specific workflow layer.
• A pilot study shows at least 20% improvement in referral-to-decision speed versus spreadsheet-based baseline.
• Retina investigators endorse at least 2 at-home tasks as operationally useful and acceptable for repeated deployment.
• The first paid RP deployment yields a credible path into at least 2 adjacent ophthalmology indications within 12 months.
• Horizontal vendors and CROs do not block deployment and can coexist through exports, APIs, or channel partnership.

Open diligence questions

• Which budget line actually pays for this product in an active retinal study?
• What screen-failure causes are common enough across programs to support reusable workflow logic?
• Which remote low-vision tasks are acceptable to investigators and not operationally burdensome for patients?
• How many near-term U.S. studies are truly available to a startup in the next 24 months?
• How hard would it be for Veeva, Medable, Signant, or a CRO to add a comparable retina template?

Model sanity

• Revenue engine. Base-case revenue is driven by reaching 7 active study contracts by Q4Y3 at about $336K blended annual revenue per study after pilot-to-production conversion and adjacent-indication upsell.
• Must go right. The first RP deployment has to prove at least a 20% faster referral-to-decision workflow so buyers fund production contracts from existing recruitment or eCOA budgets.
• Model breaks if. If the company stalls at 5 active studies and remote-assessment attach stays weak, the downside case pushes cash below zero before the next round.
• Next-round proof. The next financing is justified once the company reaches 5 active studies, one adjacent-indication launch, and one channel partner with benchmark data that shows repeatable enrollment ROI.

Scenarios

Sensitivity

flowchart LR
  SponsorBudget --> ActiveStudies
  ActiveStudies --> QualifiedPatients
  QualifiedPatients --> Revenue
  Revenue --> GrossProfit
  GrossProfit --> Cash

Flags: The initial retinal beachhead is small, so the model requires adjacent indication expansion by Year 2 to reach 7 active studies. · Blended ACV assumes remote-assessment and analytics remain sellable as exploratory workflow add-ons; if investigators reject that module, pricing compresses toward the downside case. · Cash ends Y3 at only $236K, so the company still needs a follow-on round before full breakeven.

• Sponsor budgets may prioritize biology over tooling. Early-stage biotechs may resist adding new software spend unless it directly improves enrollment or endpoint quality. Mitigation: Sell against active study milestones and tie ROI to faster enrollment, fewer screen failures, and cleaner data for each enrolled patient.
• Endpoint credibility risk. Remote functional vision assessments may be viewed as supplementary rather than decision-grade by sponsors or regulators. Mitigation: Start as an operational and exploratory endpoint layer, validate against site-collected measures, and focus first on improving trial decisions rather than replacing primary endpoints.
• Narrow initial market. Inherited retinal disease trials are specialized, so the first customer pool is limited. Mitigation: Design the platform for adjacent ophthalmology programs from day one so the same workflow can expand into geographic atrophy, other retinal interventions, and post-market monitoring.